Skip to main content

Expert Panel: Initial Views on FDA Warnings for JAK Inhibitors

Dr. Jack Cush is joined by Drs. Roy Fleischmann (Dallas), Allan Gibofsky (NYC), and Artie Kavanaugh (San Diego) to discuss the 9/2/21 FDA Drug Safety Communication regarding the cardiovascular and cancer risks arising from the Pfizer 1133 (ORAL Surveillance) tofacitinib study, but also applied to baricitinib and upadacitinib.

Author Disclosures 

  • Jack Cush, MD: Advisor/Consultant: Abbvie, Novartis, Amgen, BMS. (Investigator on Pfizer 1133 trial)
  • Roy Fleischmann, MD: Consultant: AbbVie, Amgen, BMS, Galvani, Gilead, GSK, Jansen, Eli Lilly,  Novartis, Pfizer, Sanofi Aventis, UCB    Clinical Trial Grants: AbbVie, Amgen, BMS, Flexion, Galapagos, Genentech, Gilead, GSK, Horizon, Eli Lilly, Novartis, Noven, Pfizer, Regeneron, Roche, Samumed, Sanofi Aventis, Selecta, Teva, UCB, Viela, VORSO
  • Artie Kavanaugh, MD: Consultancy – AbbVie, Amgen, Celgene, Chugai, Corrona, Covagen, Galapagos, Genentech/Roche, Janssen, Merck, Novartis, Pfizer, Sanofi, UCB; Research funding – AbbVie, Amgen, Astellas, Biogen-Idec, BMS, Celgene, Genentech/Roche, HGS, Janssen, Kirin, Pfizer, Regeneron, Sanofi, UCB
  • Allan Gibofsky, MD: Speaker-AbbVie, Lilly, Pfizer   Consultant-AbbVie, Pfizer   Shareholder-Abbvie, Pfizer; Special Employee – FDA

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Disclosures
The author has received compensation as an advisor or consultant on this subject